MENU

Australian Pharmaceuticals Industries Ltd share price hits 52-week low

Australian Pharmaceuticals Industries Ltd (ASX: API) shares hit a 52-week low of $1.33 in early morning trade, following the company’s disappointing market update released yesterday. API shares have now fallen 18.50% since January 5.

API stated full year net profit after tax (NPAT) is forecast to be “marginally above” its FY2017 result, though half year performance is expected to be 9% lower than the prior corresponding period.

All-important like-for-like sales declined 2.4% across the API network for the first half of FY2018, as the company’s Priceline Pharmacy network experienced suppressed retail conditions until late in the Christmas trading period.

With consumer spending tight in Australia due to high household debt and slow wage growth, I would be surprised to see API’s sales conditions significantly improve in the near term. Rather, due to intense competition from the likes of Chemist Warehouse and the recent local launch of Amazon, I expect API’s issues to worsen.

I have previously written that the market has overplayed the impact Amazon will have on certain retailers, however I believe hair care, skincare, beauty products and health supplements are all suited to sell online. Amazon.com.au already has a large Health & Beauty sales category, immediately positioned at an advantage without the large overheads of operating bricks and mortar stores.

API’s balance sheet as of 31 August 2017 shows a company of sound financial position; sufficient cash and a relatively small amount of interest-bearing debt. API also generated significant cash from operating activities, so cash flow wasn’t a problem during the full year period either.

What I am more concerned about is the company’s future revenue and earnings in an environment of weak retail spending, intensifying competition and online disruption. I believe these three major factors will mean decreasing store sales for API and tighter margins, likely translating into lower earnings.

For the year ended 31 August 2017, API’s statutory net profit margin was 1.29%, down from 1.35% the previous year. Given the company is already suffering from declining sales, margins may have to be cut further in order to maintain market position.

API shares are relatively cheap, currently trading for 13x trailing earnings after a 30% fall in price over the last year, though I still won’t be looking to invest until Australian consumer spending shows strong signs of improvement. Even then, I would have to see API focus more intently on conducting business online and look to streamline its store network.

OUR #1 dividend pick to grow your wealth over the new financial year is revealed for FREE here!

Financial year 2018 is here and The Motley Fool's dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.

You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.

Motley Fool contributor Ian Crane has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Pharmaceutical Industries Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.